Lantern Pharma Highlights AI-Driven Oncology Drug Development in Upcoming Webinars
Key Insights
Lantern Pharma will host two public webinars in October to discuss AI's role in oncology drug development, focusing on brain and childhood cancers (search).
The webinars will showcase Lantern's RADR® AI platform and its impact on advancing drug candidates LP-184 and LP-284, both in Phase 1 trials.
A key topic will be Lantern's blood-brain-barrier penetrability algorithm, crucial for LP-184's development in CNS cancers like glioblastoma (search).
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-focused oncology drug development company, is set to host and participate in two public webinars during October, highlighting the role of artificial intelligence in transforming cancer therapy development. These webinars will showcase the company's RADR® AI platform and its impact on accelerating the development of novel cancer treatments, particularly for brain and childhood cancers (search).
The first webinar, scheduled for October 28th, will feature CEO Panna Sharma discussing how AI is being leveraged to develop therapies for brain and childhood cancers (search). The second webinar, on October 30th, will host Actuate Therapeutics (search)' COO Andrew Mazar, who will discuss how Lantern's AI platform accelerated the development of Actuate's drug candidate, Elragllusib (search).
RADR® AI Platform and Drug Development
Lantern Pharma's RADR® platform is central to its drug development strategy. The webinars will detail how big data and AI are used to develop LP-184 and LP-284, both currently in Phase 1 clinical trials. These trials are designed to assess the safety and preliminary efficacy of these drug candidates in select patient populations.
Lantern will also discuss its blood-brain-barrier (BBB) penetrability algorithm, which is particularly important for LP-184's development in central nervous system (CNS) cancer indications, including glioblastoma (search). The ability of a drug to cross the BBB is critical for treating brain tumors effectively.
Regulatory Designations and Unmet Needs
Lantern Pharma has received four Rare Pediatric Disease Designations and the FDA's Fast Track Designation for glioblastoma (search). These designations underscore the company's progress in addressing critical unmet needs in oncology, particularly in rare and aggressive cancers.
Collaboration with Actuate Therapeutics
The October 30th webinar will focus on Lantern's AI-focused collaboration with Actuate Therapeutics (search). Andrew Mazar, Ph.D., COO of Actuate, and Lantern’s computational biologist Joseph McDermott, Ph.D., will discuss the multi-year research and development collaboration that accelerated the development of Actuate’s lead drug candidate, Elraglusib. This collaboration highlights the potential of AI to streamline drug development and identify biomarkers for patient selection.